Duncan I. Mackie
Research Subjects
Duncan I. Mackie has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- David L. Roman
Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, United States
4 shared publications - Kathleen M. Caron
University of North Carolina at Chapel Hill
4 shared publications - Natalie R. Nielsen
Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
3 shared publications Ashley Brooks-Russell
Colorado School of Public Health, Injury and Violence Prevention Center, Aurora, Colorado, United States of America
2 shared publicationsJulia Wrobel
Emory University, Rollins School of Public Health, Department of Biostatistics and Bioinformatics, Atlanta, Georgia, United States of America
2 shared publicationsReema B. Davis
Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
2 shared publications
Latest Publications
- 17 September 2026
- Published by SAGE Publications in Cannabis & Cannabinoid Research
THC Labeling Discrepancies Across Cannabis Flower Product Subtypes in a State-Legal Market
Introduction: High-concentration delta-9-tetrahydrocannabinol (THC) products, with limited research, are becoming accessible in a rapidly expanding cannabis market. There is concern about poor labeling accuracy for THC in recreationally available cannabis, which could impact public health and consumer safety. However, coarse and fine-grained data representative of the scope of legal-market cannabis products have not been reported. This project aimed to investigate THC labeling discrepancies in recreational cannabis flower products and extend examinations to the accuracy of representative cannabis flower subtypes commonly available in a state-legal market. Materials and Methods: Products were purchased between November 2022 and March 2025 from 59 licensed dispensaries across Colorado and analyzed for discrepancies in labeled versus observed THC concentration (%). Cannabis flower products ( N = 265) were included and further divided into pre-pack ( n = 76), pre-roll ( n = 27), re-pack ( n = 55), and deli ( n = 107) subtypes. Based on regulatory guidelines, product accuracy was determined by evaluating whether observed THC concentration (%) was within ± 15% of labeled THC concentration (%), and was further evaluated by product subtype. Results: Half (51.7%) of the flower products sampled were accurately labeled. Labeling accuracy ( χ 2 (6) = 15.15, p = 0.02) and the percent deviation from labeled THC concentration (%) (H = 14.3, p < 0.001) depended on product subtype. Post hoc comparisons for product accuracy indicated that pre-roll products were more likely to be over-labeled (59.3%), and re-pack products had the greatest proportions of mislabeled products that were over-labeled (96.0%). Furthermore, post hoc comparisons indicated that pre-roll products had the greatest deviation from labeled THC concentration (19.6%). Conclusion: Consistent with previous findings, recreational flower products were inaccurately labeled for THC. While all flower product subtypes demonstrated low labeling accuracy, it was observed that products subject to greater handling by dispensaries (i.e., pre-roll and re-pack) were more prone to THC over-labeling inaccuracies. Future research should explore how these findings impact consumer trust, consumption, and purchasing habits.
- 17 September 2026
- Published by SAGE Publications in Cannabis & Cannabinoid Research
THC Labeling Discrepancies Across Cannabis Flower Product Subtypes in a State-Legal Market
Introduction: High-concentration delta-9-tetrahydrocannabinol (THC) products, with limited research, are becoming accessible in a rapidly expanding cannabis market. There is concern about poor labeling accuracy for THC in recreationally available cannabis, which could impact public health and consumer safety. However, coarse and fine-grained data representative of the scope of legal-market cannabis products have not been reported. This project aimed to investigate THC labeling discrepancies in recreational cannabis flower products and extend examinations to the accuracy of representative cannabis flower subtypes commonly available in a state-legal market. Materials and Methods: Products were purchased between November 2022 and March 2025 from 59 licensed dispensaries across Colorado and analyzed for discrepancies in labeled versus observed THC concentration (%). Cannabis flower products ( N = 265) were included and further divided into pre-pack ( n = 76), pre-roll ( n = 27), re-pack ( n = 55), and deli ( n = 107) subtypes. Based on regulatory guidelines, product accuracy was determined by evaluating whether observed THC concentration (%) was within ± 15% of labeled THC concentration (%), and was further evaluated by product subtype. Results: Half (51.7%) of the flower products sampled were accurately labeled. Labeling accuracy ( χ 2 (6) = 15.15, p = 0.02) and the percent deviation from labeled THC concentration (%) (H = 14.3, p < 0.001) depended on product subtype. Post hoc comparisons for product accuracy indicated that pre-roll products were more likely to be over-labeled (59.3%), and re-pack products had the greatest proportions of mislabeled products that were over-labeled (96.0%). Furthermore, post hoc comparisons indicated that pre-roll products had the greatest deviation from labeled THC concentration (19.6%). Conclusion: Consistent with previous findings, recreational flower products were inaccurately labeled for THC. While all flower product subtypes demonstrated low labeling accuracy, it was observed that products subject to greater handling by dispensaries (i.e., pre-roll and re-pack) were more prone to THC over-labeling inaccuracies. Future research should explore how these findings impact consumer trust, consumption, and purchasing habits.
- Open Access
- 15 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0321832
Commercial cannabis product testing: Fidelity to labels and regulations
Background: In Colorado, regulations for recreational and medical cannabis sales require tetrahydrocannabinol (THC) concentration is printed on all products. Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of the THC concentration in the cannabis product and there is evidence consumers make purchasing decisions based on label claims. Aims: Explore the accuracy of cannabis product labels and differences between THC label accuracy and product type. Design: Data for this analysis come from a larger observational study of cannabis impairment. N = 74 flower, concentrate, and edible product samples from licensed Colorado dispensaries were collected and independently tested for THC concentration. Setting: This study was conducted in Colorado, in the Denver Metro Area. Participants: Participants in the study voluntarily enrolled and provided one-gram samples of the cannabis they consumed during the study to be independently tested. The cannabis tested for this analysis was donated on a voluntary basis, not all participants chose to donate. Measurement: The main outcomes of interest for this analysis are accuracy of cannabis product labels compared to observed THC content, accuracy in the context of legally allowable variation, and difference between accuracy by product. Findings: Overall, label values were higher than observed values in flower and edible products (p < 0.001) but was not significant for concentrates (p = 0.85). Flower products were observed to be significantly lower on labels versus the 15% legally allowable range (p = 0.04). Concentrate and edible products were not significantly different (p = 0.9 and p = 0.5, respectively). Conclusions: There is tension between legally allowable THC concentration claims on cannabis product labels and how consumers purchase cannabis. As cannabis policy evolves, standards and regulations that ensure accurate THC concentrations are reported on product labels are urgently needed.
- 15 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0321832
Open AccessCommercial cannabis product testing: Fidelity to labels and regulations
Background: In Colorado, regulations for recreational and medical cannabis sales require tetrahydrocannabinol (THC) concentration is printed on all products. Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of the THC concentration in the cannabis product and there is evidence consumers make purchasing decisions based on label claims. Aims: Explore the accuracy of cannabis product labels and differences between THC label accuracy and product type. Design: Data for this analysis come from a larger observational study of cannabis impairment. N = 74 flower, concentrate, and edible product samples from licensed Colorado dispensaries were collected and independently tested for THC concentration. Setting: This study was conducted in Colorado, in the Denver Metro Area. Participants: Participants in the study voluntarily enrolled and provided one-gram samples of the cannabis they consumed during the study to be independently tested. The cannabis tested for this analysis was donated on a voluntary basis, not all participants chose to donate. Measurement: The main outcomes of interest for this analysis are accuracy of cannabis product labels compared to observed THC content, accuracy in the context of legally allowable variation, and difference between accuracy by product. Findings: Overall, label values were higher than observed values in flower and edible products (p < 0.001) but was not significant for concentrates (p = 0.85). Flower products were observed to be significantly lower on labels versus the 15% legally allowable range (p = 0.04). Concentrate and edible products were not significantly different (p = 0.9 and p = 0.5, respectively). Conclusions: There is tension between legally allowable THC concentration claims on cannabis product labels and how consumers purchase cannabis. As cannabis policy evolves, standards and regulations that ensure accurate THC concentrations are reported on product labels are urgently needed.
- Open Access
Commercial Cannabis Product Testing: Fidelity to Labels and Regulations
Background: In Colorado, regulations for recreational and medical cannabis sales require Tetrahydrocannabinol (THC) concentration is printed on all products. Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of the THC concentration in the cannabis product and there is evidence consumers make purchasing decisions based on label claims. Aims: Explore the accuracy of cannabis product labels and differences between THC label accuracy and product type. Design: Data for this analysis come from a larger observational study of cannabis impairment. N=74 flower, concentrate, and edible product samples from licensed Colorado dispensaries were collected and independently tested for THC concentration. Setting: This study was conducted in Colorado, in the Denver Metro Area. Participants: Participants in the study voluntarily enrolled and provided one-gram samples of the cannabis they consumed during the study to be independently tested. The cannabis tested for this analysis was donated on a voluntary basis, not all participants chose to donate. Measurement: The main outcomes of interest for this analysis are accuracy of cannabis product labels compared to observed THC content, accuracy in the context of legally allowable variation, and difference between accuracy by product. Findings: Overall, label values were higher than observed values in flower and edible products (p < 0.001) but was not significant for concentrates (p = 0.85). Flower products were observed to be significantly lower on labels versus the 15% legally allowable range (p = 0.04). Concentrate and edible products were not significantly different (p = 0.9 and p = 0.5, respectively). Conclusions: There is tension between legally allowable THC concentration claims on cannabis product labels and how consumers purchase cannabis. As cannabis policy evolves, standards and regulations that ensure accurate THC concentrations are reported on product labels are urgently needed.
Open AccessCommercial Cannabis Product Testing: Fidelity to Labels and Regulations
Background: In Colorado, regulations for recreational and medical cannabis sales require Tetrahydrocannabinol (THC) concentration is printed on all products. Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of the THC concentration in the cannabis product and there is evidence consumers make purchasing decisions based on label claims. Aims: Explore the accuracy of cannabis product labels and differences between THC label accuracy and product type. Design: Data for this analysis come from a larger observational study of cannabis impairment. N=74 flower, concentrate, and edible product samples from licensed Colorado dispensaries were collected and independently tested for THC concentration. Setting: This study was conducted in Colorado, in the Denver Metro Area. Participants: Participants in the study voluntarily enrolled and provided one-gram samples of the cannabis they consumed during the study to be independently tested. The cannabis tested for this analysis was donated on a voluntary basis, not all participants chose to donate. Measurement: The main outcomes of interest for this analysis are accuracy of cannabis product labels compared to observed THC content, accuracy in the context of legally allowable variation, and difference between accuracy by product. Findings: Overall, label values were higher than observed values in flower and edible products (p < 0.001) but was not significant for concentrates (p = 0.85). Flower products were observed to be significantly lower on labels versus the 15% legally allowable range (p = 0.04). Concentrate and edible products were not significantly different (p = 0.9 and p = 0.5, respectively). Conclusions: There is tension between legally allowable THC concentration claims on cannabis product labels and how consumers purchase cannabis. As cannabis policy evolves, standards and regulations that ensure accurate THC concentrations are reported on product labels are urgently needed.
- 27 February 2020
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 41 (4) , 249-265
Dawn of a New RAMPage
- 27 February 2020
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 41 (4) , 249-265
Dawn of a New RAMPage
- 11 November 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (48) , 24093-24099
RAMP3 determines rapid recycling of atypical chemokine receptor-3 for guided angiogenesis
Significance: G-protein–coupled receptors (GPCRs) exist within multi-protein complexes on the surface of cells in order to respond to a wide variety of extracellular stimuli such as neurotransmitters, migratory cues, hormones, light, and odors. In this study, we discover and characterize an expanded repertoire of GPCRs that interact with receptor-activity–modifying proteins (RAMPs)—a class of proteins that can modulate the type and consequences of extracellular signals to GPCRs. Specifically, we find that RAMP interaction with chemokine GPCRs is essential for enabling these receptors to bind and degrade extracellular migratory cues and thereby establish gradients for directed cellular migration. In the absence of these critical proteins, the process of blood vessel sprouting within the postnatal retina is dysfunctional.
- 11 November 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (48) , 24093-24099
RAMP3 determines rapid recycling of atypical chemokine receptor-3 for guided angiogenesis
Significance: G-protein–coupled receptors (GPCRs) exist within multi-protein complexes on the surface of cells in order to respond to a wide variety of extracellular stimuli such as neurotransmitters, migratory cues, hormones, light, and odors. In this study, we discover and characterize an expanded repertoire of GPCRs that interact with receptor-activity–modifying proteins (RAMPs)—a class of proteins that can modulate the type and consequences of extracellular signals to GPCRs. Specifically, we find that RAMP interaction with chemokine GPCRs is essential for enabling these receptors to bind and degrade extracellular migratory cues and thereby establish gradients for directed cellular migration. In the absence of these critical proteins, the process of blood vessel sprouting within the postnatal retina is dysfunctional.
- Open Access
- 16 August 2018
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 215 (9) , 2339-2353
h CALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia
We report the first case of nonimmune hydrops fetalis (NIHF) associated with a recessive, in-frame deletion of V205 in the G protein–coupled receptor, Calcitonin Receptor-Like Receptor (hCALCRL). Homozygosity results in fetal demise from hydrops fetalis, while heterozygosity in females is associated with spontaneous miscarriage and subfertility. Using molecular dynamic modeling and in vitro biochemical assays, we show that the hCLR(V205del) mutant results in misfolding of the first extracellular loop, reducing association with its requisite receptor chaperone, receptor activity modifying protein (RAMP), translocation to the plasma membrane and signaling. Using three independent genetic mouse models we establish that the adrenomedullin–CLR–RAMP2 axis is both necessary and sufficient for driving lymphatic vascular proliferation. Genetic ablation of either lymphatic endothelial Calcrl or nonendothelial Ramp2 leads to severe NIHF with embryonic demise and placental pathologies, similar to that observed in humans. Our results highlight a novel candidate gene for human congenital NIHF and provide structure–function insights of this signaling axis for human physiology.
- 16 August 2018
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 215 (9) , 2339-2353
Open Accessh CALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia
We report the first case of nonimmune hydrops fetalis (NIHF) associated with a recessive, in-frame deletion of V205 in the G protein–coupled receptor, Calcitonin Receptor-Like Receptor (hCALCRL). Homozygosity results in fetal demise from hydrops fetalis, while heterozygosity in females is associated with spontaneous miscarriage and subfertility. Using molecular dynamic modeling and in vitro biochemical assays, we show that the hCLR(V205del) mutant results in misfolding of the first extracellular loop, reducing association with its requisite receptor chaperone, receptor activity modifying protein (RAMP), translocation to the plasma membrane and signaling. Using three independent genetic mouse models we establish that the adrenomedullin–CLR–RAMP2 axis is both necessary and sufficient for driving lymphatic vascular proliferation. Genetic ablation of either lymphatic endothelial Calcrl or nonendothelial Ramp2 leads to severe NIHF with embryonic demise and placental pathologies, similar to that observed in humans. Our results highlight a novel candidate gene for human congenital NIHF and provide structure–function insights of this signaling axis for human physiology.
- 16 June 2017
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 80 (7) , 1992-2000
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines
Regulator of G Protein Signaling (RGS) 17 is an overexpressed promoter of cancer survival in lung and prostate tumors, the knockdown of which results in decreased tumor cell proliferation in vitro. Identification of drug-like molecules inhibiting this protein could ameliorate the RGS17’s pro-tumorigenic effect. Using high-throughput screening, a chemical library containing natural products was interrogated for inhibition of the RGS17–Gαo interaction. Initial hits were verified in control and counter screens. Leads were characterized via biochemical, mass spectrometric, Western blot, microscopic, and cytotoxicity measures. Four known compounds (1–4) were identified with IC50 values ranging from high nanomolar to low micromolar. Three compounds were extensively characterized biologically, demonstrating cellular activity determined by confocal microscopy, and two compounds were assessed via ITC exhibiting high nanomolar to low micromolar dissociation constants. The compounds were found to have a cysteine-dependent mechanism of binding, verified through site-directed mutagenesis and cysteine reactivity assessment. Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products.
- 16 June 2017
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 80 (7) , 1992-2000
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines
Regulator of G Protein Signaling (RGS) 17 is an overexpressed promoter of cancer survival in lung and prostate tumors, the knockdown of which results in decreased tumor cell proliferation in vitro. Identification of drug-like molecules inhibiting this protein could ameliorate the RGS17’s pro-tumorigenic effect. Using high-throughput screening, a chemical library containing natural products was interrogated for inhibition of the RGS17–Gαo interaction. Initial hits were verified in control and counter screens. Leads were characterized via biochemical, mass spectrometric, Western blot, microscopic, and cytotoxicity measures. Four known compounds (1–4) were identified with IC50 values ranging from high nanomolar to low micromolar. Three compounds were extensively characterized biologically, demonstrating cellular activity determined by confocal microscopy, and two compounds were assessed via ITC exhibiting high nanomolar to low micromolar dissociation constants. The compounds were found to have a cysteine-dependent mechanism of binding, verified through site-directed mutagenesis and cysteine reactivity assessment. Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products.
- Open Access
- 25 November 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e80228
RABL6A, a Novel RAB-Like Protein, Controls Centrosome Amplification and Chromosome Instability in Primary Fibroblasts
RABL6A (RAB-like 6 isoform A) is a novel protein that was originally identified based on its association with the Alternative Reading Frame (ARF) tumor suppressor. ARF acts through multiple p53-dependent and p53-independent pathways to prevent cancer. How RABL6A functions, to what extent it depends on ARF and p53 activity, and its importance in normal cell biology are entirely unknown. We examined the biological consequences of RABL6A silencing in primary mouse embryo fibroblasts (MEFs) that express or lack ARF, p53 or both proteins. We found that RABL6A depletion caused centrosome amplification, aneuploidy and multinucleation in MEFs regardless of ARF and p53 status. The centrosome amplification in RABL6A depleted p53−/− MEFs resulted from centrosome reduplication via Cdk2-mediated hyperphosphorylation of nucleophosmin (NPM) at threonine-199. Thus, RABL6A prevents centrosome amplification through an ARF/p53-independent mechanism that restricts NPM-T199 phosphorylation. These findings demonstrate an essential role for RABL6A in centrosome regulation and maintenance of chromosome stability in non-transformed cells, key processes that ensure genomic integrity and prevent tumorigenesis.
- 25 November 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e80228
Open AccessRABL6A, a Novel RAB-Like Protein, Controls Centrosome Amplification and Chromosome Instability in Primary Fibroblasts
RABL6A (RAB-like 6 isoform A) is a novel protein that was originally identified based on its association with the Alternative Reading Frame (ARF) tumor suppressor. ARF acts through multiple p53-dependent and p53-independent pathways to prevent cancer. How RABL6A functions, to what extent it depends on ARF and p53 activity, and its importance in normal cell biology are entirely unknown. We examined the biological consequences of RABL6A silencing in primary mouse embryo fibroblasts (MEFs) that express or lack ARF, p53 or both proteins. We found that RABL6A depletion caused centrosome amplification, aneuploidy and multinucleation in MEFs regardless of ARF and p53 status. The centrosome amplification in RABL6A depleted p53−/− MEFs resulted from centrosome reduplication via Cdk2-mediated hyperphosphorylation of nucleophosmin (NPM) at threonine-199. Thus, RABL6A prevents centrosome amplification through an ARF/p53-independent mechanism that restricts NPM-T199 phosphorylation. These findings demonstrate an essential role for RABL6A in centrosome regulation and maintenance of chromosome stability in non-transformed cells, key processes that ensure genomic integrity and prevent tumorigenesis.
- 4 June 2013
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 5 (9) , 995-1007
RGS17: An Emerging Therapeutic Target for Lung and Prostate Cancers
Ligands for G-protein-coupled receptors (GPCRs) represent approximately 50% of currently marketed drugs. RGS proteins modulate heterotrimeric G proteins and, thus, GPCR signaling, by accelerating the intrinsic GTPase activity of the Gα subunit. Given the prevalence of GPCR targeted therapeutics and the role RGS proteins play in G protein signaling, some RGS proteins are emerging as targets in their own right. One such RGS protein is RGS17. Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer. High-throughput screening is a powerful tool for lead compound identification, and utilization of high-throughput technologies has led to the discovery of several RGS inhibitors, thus far. As screening technologies advance, the identification of novel lead compounds the subsequent development of targeted therapeutics appears promising.
- 4 June 2013
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 5 (9) , 995-1007
RGS17: An Emerging Therapeutic Target for Lung and Prostate Cancers
Ligands for G-protein-coupled receptors (GPCRs) represent approximately 50% of currently marketed drugs. RGS proteins modulate heterotrimeric G proteins and, thus, GPCR signaling, by accelerating the intrinsic GTPase activity of the Gα subunit. Given the prevalence of GPCR targeted therapeutics and the role RGS proteins play in G protein signaling, some RGS proteins are emerging as targets in their own right. One such RGS protein is RGS17. Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer. High-throughput screening is a powerful tool for lead compound identification, and utilization of high-throughput technologies has led to the discovery of several RGS inhibitors, thus far. As screening technologies advance, the identification of novel lead compounds the subsequent development of targeted therapeutics appears promising.